President Trump recently criticized the FDA approval process as "slow and burdensome" but failed to offer up specific plans for reform. If FDA standards were to be altered, the market could see an avalanche of new drugs and treatments. TheStreet's Adam Feuerstein compiled the "Gnarly Nine" companies that could be interesting to watch as the FDA enters the Trump era. 

  1. Alkermes (ALKS)
  2. CytRX (CYTR)

  3. Dynavax Technologies (DVAX)

  4. Intra-Cellular Therapies (ITCI)

  5. Novan (NOVN)

  6. Portola Pharmaceuticals (PTLA)

  7. PTC Therapeutics (PTCT)

  8. Rigel Pharmaceuticals (RIGL)

  9. TG Therapeutics (TGTX)

READ THE FULL STORY HERE: These 'Gnarly 9' Biotechs Will Test the FDA's Mettle

This article was written by a staff member of TheStreet.

More from Video

Real Money Video Wrap: GE Jumps as Analysts Look to Price in Bottom

Real Money Video Wrap: GE Jumps as Analysts Look to Price in Bottom

What the Trade Truce Means for the Markets

What the Trade Truce Means for the Markets

The 9 Highest - Paid CEOs

The 9 Highest - Paid CEOs

Stocks End Indecisively, General Electric Rises, Key Trends You Need to Watch

Stocks End Indecisively, General Electric Rises, Key Trends You Need to Watch

Yield Curve May Not Indicate a Recession -- What It Means for Stock Investors

Yield Curve May Not Indicate a Recession -- What It Means for Stock Investors